ADVERTISEMENT
Combination Products
![News We’re Watching: AMP Sues FDA To Block Lab-Developed Test Rule; FDA Guidances; ICU Medical Infusion Pump Correction](https://insights.citeline.com/resizer/v2/O2YHWUC6QJNLNOYIUU7RISZF4I.png?auth=2907107f241cc847825360405412216805b03282309f9f371179759e5cb66dce&width=400)
This week, a medical group sued the FDA to block a lab-developed test rule; the FDA published guidance on device classifications; Defibtec issued a recall of its chest compression device and ICU Medical updated instructions for its infusion pump batteries; Maui Imaging raised a $4m DOD grant to put imaging tech into military-based trauma units.
![FDA Drops Draft Guidance on Predetermined Change Control Plans for Medical Devices](https://insights.citeline.com/resizer/v2/RSTOX7FG25OT5FKJQS4M7CLC6U.jpg?auth=9854ea17bc0f715cc0d45b623d6299691c81e1b3f85dd07d2c5cd6e33ccf3217&width=400)
The US FDA has published draft guidance for predetermined change control plans for medical devices along with recommendations for sponsors including them in marketing submissions to the agency.
![Q&A Guidance Doc Dives Into Combination Product User Fees](https://insights.citeline.com/resizer/v2/ZXUYXJKD3BNITMCYZE7MVMPOIU.jpg?auth=9ba3f13f4c29725dbcc74629f0fed457bb98c1ce9b8625fe357c5a719bd1c9ef&width=400)
The document explains how user fees for combination products are assessed and administered, as well as waiver possibilities.
![Orange Book Is The New Spat: FTC Seeks Removal Of ‘Improperly’ Listed Medical Device Patents](https://insights.citeline.com/resizer/v2/4M6RSZJWNBKZDHCMRF24R5T4VI.jpg?auth=27e375957567ec02a687d88bf9aca25edf0df29aac483d34fc2fa8be26bce3ec&width=400)
The US Federal Trade Commission wants to clean up the FDA’s Orange Book by purging medical device patents that the commission says should not be in the listing. The FTC argues improper patents in the Orange Book block lower-cost generic equivalents from coming to market. Medtech Insight spoke to attorney Sara Koblitz about the FTC’s delisting push.
![FDA Offers Draft Guidance For Developers Of Drug Delivery Devices](https://insights.citeline.com/resizer/v2/MF7XIFRUQNPFJALFMDKVZRYC4A.jpg?auth=28d87e73333e8025743f59ced63e2d7b88538e3361b24a59c0b87e1a6b124600&width=400)
The US FDA has published draft guidance for developers of drug delivery devices listing recommendations related to device design outputs essential for establishing and assessing the performance of their products.
![ADDF Leaders Discuss Future Strategies In Alzheimer’s Research And Crucial Role Of Diagnostic Markers](https://insights.citeline.com/resizer/v2/JSMCKYEUUROSDCY25DNLMOKMBU.png?auth=bcd64ac33adcbfa292b621420c28bdf97bf063bfe3aba27e1d2b1dca9efeecd8&width=400)
Medtech Insight talked to two leaders at the Alzheimer’s Drug Discovery Foundation about current therapies and the role of biomarkers and digital tools to build on recent advancements in the space and accelerate progress to identify the disease early and slow cognitive decline.
![EMA Answers More Questions For Manufacturers of Drug-Device Combos](https://insights.citeline.com/resizer/v2/SNUQNIKMZBNILDAWTJPSNV6KIY.jpg?auth=ac0a0f13f476ed7bf9419c0f69fc0372fb5f917bf260b8893f62776141b5870a&width=400)
Will it be necessary to provide a new medical device notified body opinion when changes are being made to the medicine in an integral drug-device combination product? This is just one of the new topics addressed in an updated Q&A document from the European Medicines Agency.
![EMA Answers More Questions For Manufacturers of Drug-Device Combos](https://insights.citeline.com/resizer/v2/AL6SCXHCN5L7RNMNHKRJFL4LP4.jpg?auth=be02eac231f2707ca43fcbb8f732a7044d1fe4fe279d19f6921fba5d93f6d0c0&width=400)
Will it be necessary to provide a new medical device notified body opinion when changes are being made to the medicine in an integral drug-device combination product? This is just one of the new topics addressed in an updated Q&A document from the European Medicines Agency.
![Senseonics Wins Marketing Authorization For Novel Insulin Delivery System](https://insights.citeline.com/resizer/v2/DJ3XG5LEHNMIPLUODF7LMWEZD4.jpg?auth=28940ec60a67eeb2d1f9218a687092987506f85f4497d68a4d75c7edcf9542e6&width=400)
The US FDA has cleared a glucose monitoring system from Senseonics. The authorization of the implantable insulin delivery system creates a new pathway for like devices.
![News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR](https://insights.citeline.com/resizer/v2/ZN44SGBJIRKXZLCKVZ2IZPFS74.png?auth=f5a8212cf17fb52de51e40799deb1a0b6b0afa5a7d7a50c1c98e9def6a38338e&width=400)
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.